Canadian Cannabis Giant Canopy Grows Global Medical Footprint, Launches These Products

Cannabis giant Canopy Growth Corporation (TSX: WEED) (NASDAQ: CGC) has expanded its Spectrum Therapeutics portfolio in Australia, further bolstering its medical cannabis offerings in the region.

“Expanding our portfolio in established markets like Australia is a key driver of our global medical strategy,” Luc Mongeau, the company’s CEO, said. “Softgels deepen our offering and reinforce our commitment to meeting the needs of patients in this important international market.”

The formats include:

• Spectrum Yellow Cannabis Oil Softgels (CBD 20mg);
• Spectrum Red Cannabis Oil Softgels (THC 10mg); and
• Spectrum Blue Cannabis Oil Softgels (Balanced THC 2.5mg : CBD 3.75mg).

Spectrum Therapeutics softgel capsules are available to patients in Australia via authorized prescribers, complementing Spectrum Therapeutics’ existing oils and flower, as well as flower products from Tweed, 7ACRES, and TWD, which are already available.

“Patients continue to ask for a variety of formats that deliver both quality and convenience,” Andrew Bevan, SVP of Global Medical, said. “Adding softgels to the Spectrum Therapeutics portfolio gives prescribers and patients more choice while supporting the continued growth of our international business.”

Canopy Growth Corporation recently reported strong second-quarter of fiscal 2026 results marked by double-digit growth in Canadian cannabis sales, a 63% reduction in operating loss, and a strengthened cash position.